http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022130196-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d289a3479a27e7d170a185a9006cafda
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-10143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-902
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
filingDate 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d25a32569c6a741e220acfe97610cb82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cf233158eaa2119cf89df8d33fdbdc8
publicationDate 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022130196-A1
titleOfInvention Universal bacteriophage t4 nanoparticle platform to design multiplex sars-cov-2 vaccine candidates by crispr engineering
abstract The present disclosure relates to a system for and a method of incorporating SARS-CoV-2 genes and proteins into T4 phages. The present disclosure also relates to vaccine against SARS-CoV-2 containing recombinant T4 phages created using the method provided in the present disclosure.
priorityDate 2020-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019330643-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018191750-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014135998-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3034398
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18643904
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395691
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406479
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395685
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104981
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41206
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11333924
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395099
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400530
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24186254
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400531
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15541
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6694
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412246
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400532
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405512

Total number of triples: 55.